Antitumor effect of intrapleural administration of Lactobacillus casei in mice

Cancer Immunol Immunother. 1988;26(3):209-14. doi: 10.1007/BF00199931.

Abstract

The antitumor effect of intrapleural (i.pl.) administration of Lactobacillus casei YIT 9018 (LC 9018) on Meth A sarcoma in BALB/c mice was examined. Inoculation of Meth A cells into the thoracic cavity of BALB/c mice caused growth of the cells and the mice died from the tumor with an increased amount of pleural fluid. LC 9018 was given i.pl. to BALB/c mice before or after i.pl. inoculation of Meth A cells and the survival of the mice was determined. The i.pl. administration of LC 9018 was effective in prolonging the survival of the mice after i.pl. inoculation of Meth A tumor, and pretreatment with LC 9018 i.pl. also prolonged survival. Moreover, i.pl. administration of LC 9018 not only increased the number of thoracic exudate cells (TEC) but also augmented both cytolytic activity of thoracic macrophages and natural killer cell activity of TEC. Furthermore, phagocytic activity of thoracic macrophages against sheep red blood cells was enhanced and Ia antigen-positive cells in TEC were increased by the i.pl. treatment with LC 9018. These results showed that TEC induced by i.pl. administration of LC 9018 had antitumor activity against Meth A tumor inoculated i.pl. into BALB/c mice.

MeSH terms

  • Adjuvants, Immunologic / administration & dosage*
  • Adjuvants, Immunologic / therapeutic use
  • Animals
  • Ascitic Fluid / immunology
  • Ascitic Fluid / pathology
  • Cell Count
  • Cell Division
  • Cytotoxicity, Immunologic
  • Histocompatibility Antigens Class II / analysis
  • Injections
  • Killer Cells, Natural / immunology
  • Lacticaseibacillus casei / immunology*
  • Macrophages / immunology
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Phagocytosis
  • Pleura
  • Sarcoma, Experimental / mortality
  • Sarcoma, Experimental / pathology
  • Sarcoma, Experimental / therapy*
  • Thoracic Neoplasms / immunology
  • Thoracic Neoplasms / pathology

Substances

  • Adjuvants, Immunologic
  • Histocompatibility Antigens Class II